A Role of BDNF in the Depression Pathogenesis and a Potential Target as Antidepressant: The Modulator of Stress Sensitivity “Shati/Nat8l-BDNF System” in the Dorsal Striatum
Open accessThe DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Abstract
Depression is one of the most common mental diseases, with increasing numbers of patients globally each year. In addition, approximately 30% of patients with depression are resistant to any treatment and do not show an expected response to first-line antidepressant drugs. Therefore, novel antidepressant agents and strategies are required. Although depression is triggered by post-birth stress, while some individuals show the pathology of depression, others remain resilient. The molecular mechanisms underlying stress sensitivity remain unknown. Brain-derived neurotrophic factor (BDNF) has both pro- and anti-depressant effects, dependent on brain region. Considering the strong region-specific contribution of BDNF to depression pathogenesis, the regulation of BDNF in the whole brain is not a beneficial strategy for the treatment of depression. We reviewed a novel finding of BDNF function in the dorsal striatum, which induces vulnerability to social stress, in addition to recent research progress regarding the brain regional functions of BDNF, including the prefrontal cortex, hippocampus, and nucleus accumbens. Striatal BDNF is regulated by Shati/Nat8l, an N-acetyltransferase through epigenetic regulation. Targeting of Shati/Nat8l would allow BDNF to be striatum-specifically regulated, and the striatal Shati/Nat8l-BDNF pathway could be a promising novel therapeutic agent for the treatment of depression by modulating sensitivity to stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“its expression is significantly reduced in brain areas such as the prefrontal cortex and hippocampus in patients with depression.”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Generally, these drugs require long periods before the effects are seen [11] and do not show high response rates in approximately 30% of patients with depression, who are resistant to treatment [12,13].”
BackgroundStress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“The presence of the BDNF Val66Met polymorphism impairs BDNF release [91] and the maturation of BDNF from proBDNF in the hippocampus [92].”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Generally, these drugs require long periods before the effects are seen [11] and do not show high response rates in approximately 30% of patients with depression, who are resistant to treatment [12,13].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“sustained antidepressant effects, even in patients with treatment resistance [162].”
BackgroundA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 4×
“Hippocampus Human [93,94,101,108] pro-depressant increasing Animal [30,102–106,109]”
BackgroundInfluentialKrishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307 · cited 4×
“Mesolimbic pathway Human [111] anti-depressant decreasing Animal [29,58,110,112,113,122]”
BackgroundInfluentialCross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221 · cited 1×
“The prevalence of depression in lifetime reached 15–18% [3], meaning that one in five people were affected by the condition in their lifetime.”
BackgroundEssential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 7×
“The role of BDNF in the central nervous system (CNS) in depression may depend on the circuit and region, with both antidepressant and antidepressant effects [29,30].”
BackgroundResultInfluential
Cited by
Jemni, M., Zaman, R., Carrick, F. R., Clarke, N. D., Marina, M., Bottoms, L. M., Matharoo, J. S., Ramsbottom, R., Hoffman, N., Groves, S. J., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1102526 · Cited by 93
“…that BDNF plays a major role in major depressive disorder (MDD) that BDNF-knockout mice are widely used to examine the experimental role of other markers, inflammatory responses, and gene expression in MDD animal models (Jodeiri Farshbaf & Alviña, 2021; Miyanishi & Nitta, 2021; Li et al., 2022).”
BackgroundProbiotics for the treatment of depression and its comorbidities: A systemic review
Gao, J., Zhao, N., Cheng, Y., Lei, W., Wang, Y., Liu, X., Zheng, N., Shao, L., Chen, X., Sun, Y., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1167116 · Cited by 87
“Thus, novel antidepressant agents and strategies are required (Miyanishi and Nitta, 2021).”
BackgroundFlavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder
Jembrek, M. J., Oršolić, N., Karlović, D., & Peitl, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086888 · Cited by 63
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
“Alterations in BDNF levels have been implicated in the pathogenesis of MDD, with evidence suggesting that reduced BDNF expression in key brain regions, such as the hippocampus and prefrontal cortex, may contribute to the development of depressive symptoms [4,5].”
Liaqat, H., Parveen, A., & Kim, S. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314968 · Cited by 53
Metadata
- Authors
- Miyanishi, H., & Nitta, A.
- Affiliations
- University of Toyama (JP)
- Corresponding author
- Nitta, Atsumi
- ORCID
- Nitta, Atsumi
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-09-01
- Volume
- 14
- Issue
- 9
- Pages
- 889
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC8469819
- OpenAlex
- W3197234894
- Cited by
- 57
- References
- 164
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 26 · 2023: 9 · 2022: 9
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (21H02632, 16H06276)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- brain-derived neurotrophic factor, depression, dorsal striatum, N-acetyltransferase, epigenetic regulation, social stress, stress sensitivity, antidepressant targets, depression vulnerability, prefrontal cortex, hippocampus, nucleus accumbens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Role of BDNF in the Depression Pathogenesis and a Potential Target as Antidepressant: The Modulator of Stress Sensitivity “Shati/Nat8l-BDNF System” in the Dorsal Striatum. https://app.cochat.ai/papers/10.3390/ph14090889
- The paper
- Miyanishi, H., & Nitta, A. (2021). A Role of BDNF in the Depression Pathogenesis and a Potential Target as Antidepressant: The Modulator of Stress Sensitivity “Shati/Nat8l-BDNF System” in the Dorsal Striatum. Pharmaceuticals. https://doi.org/10.3390/ph14090889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.